Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antineoplastic agent
implantable medical device |
| gptkbp:activeIngredient |
gptkb:carmustine
|
| gptkbp:administeredBy |
surgical implantation
|
| gptkbp:alternativeTo |
systemic chemotherapy
|
| gptkbp:approvedBy |
gptkb:FDA
1996 |
| gptkbp:ATCCode |
L01AD01
|
| gptkbp:brand |
gptkb:Gliadel
|
| gptkbp:contraindication |
hypersensitivity to carmustine
recent brain surgery infection |
| gptkbp:deliversDrug |
locally to tumor site
|
| gptkbp:developedBy |
Guilford Pharmaceuticals
|
| gptkbp:form |
biodegradable polymer wafer
|
| https://www.w3.org/2000/01/rdf-schema#label |
Carmustine wafers
|
| gptkbp:indication |
recurrent glioblastoma
newly diagnosed high-grade malignant glioma |
| gptkbp:isSolubleIn |
brain tissue
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
antineoplastic agent
|
| gptkbp:pregnancyCategory |
D
|
| gptkbp:routeOfAdministration |
intracranial
|
| gptkbp:sideEffect |
seizures
wound healing complications brain edema intracranial infection |
| gptkbp:usedFor |
treatment of brain tumors
treatment of glioblastoma multiforme |
| gptkbp:bfsParent |
gptkb:High-grade_glioma
|
| gptkbp:bfsLayer |
8
|